March 22, 2018 2:35 PM ET

Healthcare Equipment and Supplies

Company Overview of Gamma Medica, Inc.

Company Overview

Gamma Medica, Inc. develops, manufactures, and markets digital molecular imaging systems. The company offers LumaGEM Molecular Breast Imaging system, a diagnostic tool for detecting early-stage cancers in dense breast tissue; and LumaGUIDE biopsy accessory, a lesion localization accessory used in conjunction with breast imaging systems. It also provides training, and service and maintenance contracts for its imaging systems. The company was formerly known as Gamma Medica-Ideas, Inc. and changed its name to Gamma Medica, Inc. in September 2013. The company was founded in 1997 and is based in Salem, New Hampshire.

12 Manor Parkway

Unit 3

Salem, NH 03079

United States

Founded in 1997





Key Executives for Gamma Medica, Inc.

Gamma Medica, Inc. does not have any Key Executives recorded.

Gamma Medica, Inc. Key Developments

Gamma Medica Announces Installation at Mercy Medical Center in Long Island, the Clinical Lumagem® Molecular Breast Imaging Technology to New York

Gamma Medica announced that Mercy Medical Center a member of Catholic Health Services of Long Island has purchased and installed New York’s clinical LumaGEM® Molecular Breast Imaging system. MBI is a secondary screening and diagnostic tool that is particularly useful for women who have dense breast tissue and women with a high risk of being diagnosed with cancer. It is a proven, effective supplementary screening method to mammography, significantly increasing early detection in women who are at a higher risk due to dense breast tissue.

Gamma Medica Expands into European Breast Imaging Market Through Partnership with Medical Supplies Distributor, Hospital Services Limited

Gamma Medica announced it has partnered with Hospital Services Limited. This partnership will provide women with dense breast tissue access to Gamma Medica’s LumaGEM® Molecular Breast Imaging system in the United Kingdom, Ireland and the Channel Islands.

Gamma Medica Announces Partnership with Medical Imaging, Inc. and Capital X-Ray, Inc. to Distribute its LumaGEM Molecular Breast Imaging System

Gamma Medica announced that it has partnered with Medical Imaging, Inc. and Capital X-Ray, Inc., to give women in Georgia, Louisiana, Alabama, Mississippi, Idaho and parts of Oregon, Montana, Wyoming and Washington State access to Gamma Medica’s LumaGEM® Molecular Breast Imaging (MBI) system. Molecular Breast Imaging (MBI) is a secondary screening and diagnostic tool for women with increased risk of breast cancer due to the presence of dense breast tissue. Approximately 50% of U.S. women are reported to have dense breast tissue; however, many women are unaware that they have dense breasts and if they do, they may not understand this could also mean an increased risk of breast cancer. Because dense breast tissue and cancer both appear white on mammograms, it can be difficult to distinguish between the two—it’s like trying to find a snowflake in a snowstorm. This can lead to false negatives, unwarranted biopsies or delayed diagnoses. A breakthrough retrospective clinical study published in the August issue of the American Journal of Roentgenology provided further clinical evidence that MBI is an effective supplementary screening method to standard mammography and/or tomosynthesis (3D mammography) in women who have dense breast tissue or are at higher intrinsic risk of breast cancer. This study reported that MBI was able to detect an additional 7.7 cancers per 1,000 women screened compared to mammography screening alone (3/1,000). There is also a two times improvement over ultrasound, a typical secondary modality used today. In addition, approximately 85% of these cancers were found to be invasive, of which 81% were node negative, enabling cancers to be detected at an earlier stage and presenting the patient with a likelihood of a better prognosis. This study complements an earlier published [2015] prospective blinded study that was conducted by the Mayo Clinic, Rochester, MN. To raise awareness about breast density and breast cancer screening options, Gamma Medica launched the Be Certain campaign. The campaign’s educational website aims to provide the most accurate information for physicians, patients and caregivers by sharing patient and physician testimonials, breast density facts and statistics and the latest news relating to breast density and breast screenings.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems Inc. United States
20/20 Imaging LLC United States
206 Ortho, Inc. United States
21st Century Scientific, Inc. United States

Recent Private Companies Transactions

October 6, 2017
Certain Assets and Intellectual Property of Gamma Medica, Inc.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Gamma Medica, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at